All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

methylergometrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
ergot alkaloid derivatives	1764	113-42-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: methylergometrine maleate methylergonovine methergine methergen methylergobasin methylergobasine methylergobrevin partergin methylergonovine maleate methylergometrine methylergometrin	A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed) Molecular weight: 339.44 Formula: C20H25N3O2 CLOGP: 1.76 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 68.36 ALOGS: -3.22 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	mg	O
0.20	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.96 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	7.18 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.85 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	11.39 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Nov. 19, 1946	FDA	EDISON THERAPS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Wrong product administered	70.01	37.71	17	1050	6124	63481831
Postpartum haemorrhage	41.47	37.71	9	1058	1972	63485983
Cyanosis	40.91	37.71	14	1053	16921	63471034
Disseminated intravascular coagulation	39.30	37.71	14	1053	19037	63468918
Exposure during pregnancy	38.94	37.71	27	1040	155520	63332435

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Wrong product administered	205.09	97.49	33	143	5301	34951454

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Wrong product administered	145.52	134.14	27	100	9	89656

Pharmacologic Action:

Source	Code	Description
ATC	G02AB01	GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Ergot alkaloids
ATC	G02AC01	GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Ergot alkaloids and oxytocin incl. analogues, in combination
FDA CS	M0007652	Ergolines
MeSH PA	D010120	Oxytocics
MeSH PA	D012102	Reproductive Control Agents
CHEBI has role	CHEBI:176497	geroprotectors
FDA EPC	N0000175827	Ergot Derivative

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Postpartum hemorrhage	indication	47821001
Postabortal Hemorrhage	indication
Incomplete miscarriage	off-label use	156072005
Hypertensive disorder	contraindication	38341003	DOID:10763
Pregnancy-induced hypertension	contraindication	48194001
Kidney disease	contraindication	90708001	DOID:557
Seizure disorder	contraindication	128613002
Cerebrovascular accident	contraindication	230690007
Disease of liver	contraindication	235856003	DOID:409
Sepsis syndrome	contraindication	238150007
Pregnancy, function	contraindication	289908002
Arteriosclerosis obliterans	contraindication	361133006	DOID:5160

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.56	acidic
pKa2	13.6	acidic
pKa3	7.01	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN	ANTAGONIST	Ki	6.27		DRUG MATRIX	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.56		DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.23		DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	8.63		DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	AGONIST	Ki	9.40		IUPHAR
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN	PARTIAL AGONIST	Ki	9.10		CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	AGONIST	Ki	8.30		IUPHAR
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	8.93		DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.68		DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	7.24		DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	6.70		DRUG MATRIX
5-hydroxytryptamine receptor 1F	GPCR	P30939	5HT1F_HUMAN	ANTAGONIST	Ki	7.50		IUPHAR
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN	ANTAGONIST	Ki	7.20		IUPHAR
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	8.03		DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	8.39		CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT	AGONIST	Ki	7.90		IUPHAR
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_RAT	AGONIST	Ki	7.90		IUPHAR

External reference:

ID	Source
4018757	VUID
N0000179466	NUI
D00680	KEGG_DRUG
57432-61-8	SECONDARY_CAS_RN
4018757	VANDF
4019831	VANDF
CHEBI:6874	CHEBI
H8D	PDB_CHEM_ID
CHEMBL1201356	ChEMBL_ID
CHEMBL1200843	ChEMBL_ID
150	IUPHAR_LIGAND_ID
DB00353	DRUGBANK_ID
227555	RXNORM
160889	MMSL
5091	MMSL
967	MMSL
d00587	MMSL
001306	NDDF
004941	NDDF
126074008	SNOMEDCT_US
126075009	SNOMEDCT_US
40562000	SNOMEDCT_US
C0025760	UMLSCUI
D008755	MESH_DESCRIPTOR_UI
2900	INN_ID
8226	PUBCHEM_CID
W53L6FE61V	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0639	TABLET	0.20 mg	ORAL	ANDA	20 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0639	TABLET	0.20 mg	ORAL	ANDA	20 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3655	TABLET	0.20 mg	ORAL	ANDA	20 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0517-0740	INJECTION, SOLUTION	0.20 mg	INTRAMUSCULAR	ANDA	21 sections
METHERGINE	HUMAN PRESCRIPTION DRUG LABEL	1	12634-179	TABLET, COATED	0.20 mg	ORAL	NDA	21 sections
Methylergonovine Maleate	Human Prescription Drug Label	1	16571-735	TABLET	0.20 mg	ORAL	ANDA	20 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	17478-501	INJECTION	0.20 mg	INTRAVENOUS	ANDA	21 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	17478-501	INJECTION	0.20 mg	INTRAVENOUS	ANDA	21 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-3655	TABLET	0.20 mg	ORAL	ANDA	20 sections
Methergine	HUMAN PRESCRIPTION DRUG LABEL	1	27437-050	TABLET	0.20 mg	ORAL	ANDA	18 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	40032-140	TABLET	0.20 mg	ORAL	ANDA	21 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	43386-140	TABLET	0.20 mg	ORAL	ANDA	19 sections
METHYLERGONOVINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4536	INJECTION	0.20 mg	INTRAVENOUS	ANDA	22 sections
METHYLERGONOVINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1556	INJECTION	0.20 mg	INTRAVENOUS	ANDA	13 sections
METHYLERGONOVINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	51991-144	INJECTION	0.20 mg	INTRAVENOUS	ANDA	22 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	60687-410	TABLET	0.20 mg	ORAL	ANDA	21 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	60687-410	TABLET	0.20 mg	ORAL	ANDA	21 sections
METHYLERGONOVINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2074	INJECTION	0.20 mg	INTRAVENOUS	ANDA	21 sections
METHYLERGONOVINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2074	INJECTION	0.20 mg	INTRAVENOUS	ANDA	21 sections
METHYLERGONOVINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	63704-004	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	ANDA	21 sections
methylergonovine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	63704-006	TABLET	0.20 mg	ORAL	ANDA	23 sections
Methergine	HUMAN PRESCRIPTION DRUG LABEL	1	66336-402	TABLET, COATED	0.20 mg	ORAL	NDA	22 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1605	TABLET	0.20 mg	ORAL	ANDA	20 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	70010-786	TABLET	0.20 mg	ORAL	ANDA	20 sections